Primary Autonomic Failure

Neurology and Clinical Neuroscience

Volumn , Issue , 2007, Pages 372-393

  Geser, Felix ^a   Wenning, Gregor K ^b,c,d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Clinical Neurobiology Unit   (Austria)

^c Movement Disorder Unit   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75749111687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03354-1.50034-1     Document Type: Chapter

References (240)

1. Kaufmann H, Schatz IJ Pure autonomic failure. Primer on the Autonomic Nervous System 2004, 309-311. Elsevier, Amsterdam. 2nd ed. D. Robertson (Ed.).
2. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System 1999, Oxford University Press, Oxford, UK. C. Mathias, R. Bannister (Eds.).
3. Mathias CJ, Polinsky RJ Separating the primary autonomic failure syndromes, multiple system atrophy, and pure autonomic failure from Parkinson's disease. Adv Neurol 1999, 80:353-361.
4. Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol 2004, 3:203-293.
5. Wenning GK, Stampfer M Dementia with Lewy Bodies. Primer on the Autonomic Nervous System 2004, 293-294. Elsevier, Amsterdam. 2nd ed. D. Robertson (Ed.).
6. Mathias CJ The classification and nomenclature of autonomic disorders-ending chaos, resolving conflict and hopefully achieving clarity. Clin Auton Res 1995, 5:307-310.
7. Bannister R, Mathias CJ, Polinsky R Clinical features of autonomic failure. B. Autonomic failure: a comparison between UK and US experience. Autonomic Failure. A Textbook of Disorders of the Autonomic Nervous System 1988, 281-288. Oxford University Press, Oxford. 2nd ed. R. Bannister (Ed.).
8. Kaufmann H, Hague K, Perl D Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure. Neurology 2001, 56:980-981.
9. Kaufmann H Primary autonomic failure: three clinical presentations of one disease?. Ann Intern Med 2000, 133:382-384.
10. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
11. Stefanova N, Klimaschewski L, Poewe W, et al. Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res 2001, 65:432-438.
12. Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998, 44:415-422.
13. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002, 3:583-588.
14. Hague K, Lento P, Morgello S, et al. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol (Berl) 1997, 94:192-196.
15. van Ingelghem E, van Zandijcke M, Lammens M Pure autonomic failure: a new case with clinical, biochemical, and necropsy data. J Neurol Neurosurg Psychiatry 1994, 57:745-747.
16. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993, 50:140-148.
17. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
18. Oppenheimer DR Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980, 46:393-404.
19. Graham JG, Oppenheimer DR Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969, 32:28-34.
20. van der Eecken H, Adams R, van Bogaert L Striopallidalnigral degeneration: a hitherto undescribed lesion in paralysis agitans. J Neuropathol Exp Neurol 1960, 19:159-161.
21. Adams R, Van Bogaert L, Van der Eecken H [Nigro-striate and cerebello-nigro-striate degeneration. Clinical uniqueness and pathological variability of presenile degeneration of the extrapyramidal rigidity type]. Psychiatr Neurol (Basel) 1961, 142:219-259.
22. Adams RD, Vanbogaert L, Van der Eecken H Striatonigral degeneration. J Neuropathol Exp Neurol 1964, 23:584-608.
23. Dejerine J, Thomas A L'atrophie olivo-ponto-cerebelleuse. Nouv Iconogr Salpetr 1900, 13:330-370.
24. Stauffenberg W Zur Kenntnis des extrapyramidalen motorischen Systems und Mitteilung eines Falles von sog. Atrophie olivo-pontocerbelleuse. Zeitschr Ges Neurol Psychiatrie 1918, 39:1-55.
25. Shy GM, Drager GA A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol 1960, 2:511-527.
26. Papp MI, Lantos PL The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994, 117(Pt 2):235-243.
27. Geser F, Stampfer-Kountchev M, Seppi K, et al. The clinical presentation of multiple system atrophy (MSA) in Europe: An interim analysis of the EMSA-SG (European MSA-Study Group) Registry. Mov Disord 2004, 19(Suppl 9):347.
28. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998, 8:359-362.
29. Kume A, Takahashi A, Hashizume Y Neuronal cell loss of the striatonigral system in multiple system atrophy. J Neurol Sci 1993, 117:33-40.
30. Wenning GK, Tison F, Elliott L, et al. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord 1996, 11:157-162.
31. Sung JH, Mastri AR, Segal E Pathology of Shy-Drager syndrome. J Neuropathol Exp Neurol 1979, 38:353-368.
32. Benarroch EE, Smithson IL, Low PA, et al. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol 1998, 43:156-163.
33. Benarroch EE, Schmeichel AM, Parisi JE Depletion of cholinergic neurons of the medullary arcuate nucleus in multiple system atrophy. Auton Neurosci 2001, 87:293-299.
34. Benarroch EE, Schmeichel AM, Parisi JE Depletion of mesopontine cholinergic and sparing of raphe neurons in multiple system atrophy. Neurology 2002, 59:944-946.
35. Benarroch EE Brainstem in multiple system atrophy: clinicopathological correlations. Cell Mol Neurobiol 2003, 23:519-526.
36. Nakamura S, Ohnishi K, Nishimura M, et al. Large neurons in the tuberomammillary nucleus in patients with Parkinson's disease and multiple system atrophy. Neurology 1996, 46:1693-1696.
37. Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997, 12:133-147.
38. Daniel S The neuropathology and neurochemistry of multiple system atrophy. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System 1999, 321-328. Oxford University Press, Oxford, UK. 4th ed. C. Mathias, R. Bannister (Eds.).
39. Kaufmann H, Oribe E, Miller M, et al. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992, 42:590-593.
40. Konno H, Yamamoto T, Iwasaki Y, et al. Shy-Drager syndrome and amyotrophic lateral sclerosis: cytoarchitectonic and morphometric studies of sacral autonomic neurons. J Neurol Sci 1986, 73:193-204.
41. Bannister R, Oppenheimer DR Degenerative diseases of the nervous system associated with autonomic failure. Brain 1972, 95:457-474.
42. Spokes EG, Bannister R, Oppenheimer DR Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases. J Neurol Sci 1979, 43:59-82.
43. Matthews M Autonomic ganglia and preganglionic neurons in autonomic failure. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System 1999, 329-339. Oxford University Press, Oxford, UK. 4th ed. C. Mathias, R. Bannister (Eds.).
44. Sima AA, Caplan M, D'Amato CJ, et al. Fulminant multiple system atrophy in a young adult presenting as motor neuron disease. Neurology 1993, 43:2031-2035.
45. Low PA Autonomic neuropathies. Curr Opin Neurol 1994, 7:402-406.
46. McLeod JG Autonomic dysfunction in peripheral nerve disease. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System 1999, 367-377. Oxford University Press, Oxford, UK. 4th ed. C. Mathias, R. Bannister (Eds.).
47. Suarez GA, Fealey RD, Camilleri M, et al. Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. Neurology 1994, 44:1675-1682.
48. Bennett JL, Mahalingam R, Wellish MC, et al. Epstein-Barr virus-associated acute autonomic neuropathy. Ann Neurol 1996, 40:453-455.
49. Santiago S, Ferrer T, Espinosa ML Neurophysiological studies of thin myelinated (A delta) and unmyelinated (C) fibers: application to peripheral neuropathies. Neurophysiol Clin 2000, 30:27-42.
50. Santiago S, Espinosa ML, Perez-Conde MC, et al. Small fiber dysfunction in peripheral neuropathies. Rev Neurol 1999, 28:543-554.
51. Bradbury S, Eggleston C Postural hypotension: a report of three cases. Am Heart J 1925, 1:75-86.
52. Kaufmann H Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996, 6:125-126.
53. Mathias CJ Orthostatic hypotension: causes, mechanisms, and influencing factors. Neurology 1995, 45:S6-S11.
54. Robertson D, Davis TL Recent advances in the treatment of orthostatic hypotension. Neurology 1995, 45:S26-S32.
55. Mathias CJ, Mallipeddi R, Bleasdale-Barr K Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 1999, 246:893-898.
56. Schatz IJ Orthostatic hypotension. I. Functional and neurogenic causes. Arch Intern Med 1984, 144:773-777.
57. Geser F, Stampfer-Kountchev M, Seppi K, et al. Warning signs ("red flags") in multiple system atrophy (MSA): a preliminary cross-sectional analysis of 79 European MSA-P patients. Mov Disord 2004, 19(Suppl 9):346-347.
58. Geser F, Stampfer-Kountchev M, Seppi K, et al. Warning signs ("red flags") in possible MSA: a preliminary cross-sectional analysis of the European MSA-Study Group (EMSA-SG). Funct Neurol 2004, 19:144.
59. Kaufmann H, Biaggioni I Autonomic failure in neurodegenerative disorders. Semin Neurol 2003, 23:351-363.
60. Mathias CJ, Polinsky RJ Separating the primary autonomic failure syndromes, multiple system atrophy, and pure autonomic failure from Parkinson's disease. Adv Neurol 1999, 80:353-361.
61. Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 63:228-234.
62. Magalhaes M, Wenning GK, Daniel SE, et al. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease: a retrospective comparison. Acta Neurol Scand 1995, 91:98-102.
63. Kaufmann H, Nouri S, Olanow W, et al. Orthostatic intolerance in Parkinson's disease. Neurology 1997, 48:149.
64. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 63:584-589.
65. Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999, 67:620-623.
66. Orskov L, Jakobsen J, Dupont E, et al. Autonomic function in parkinsonian patients relates to duration of disease. Neurology 1987, 37:1173-1178.
67. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992, 49:492-497.
68. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999, 14:866-874.
69. Peralta CM, Stampfer M, Karner E, et al. Orthostatic hypotension and attention in Lewy body disorders. Mov Disord 2004, 19(Suppl 9):331-332.
70. Geser F, Wenning GK, Poewe W, et al. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005, 20(Suppl 12):S11-S20.
71. McKeith IG, Perry EK, Perry RH Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999, 53:902-905.
72. Horimoto Y, Matsumoto M, Akatsu H, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol 2003, 250:530-533.
73. Ransmayr G Dementia with Lewy bodies: prevalence, clinical spectrum and natural history. J Neural Transm Suppl 2000, (60):303-314.
74. Del Ser T, McKeith I, Anand R, et al. Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000, 15:1034-1045.
75. Aarsland D, Ballard C, McKeith I, et al. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001, 13:374-379.
76. Pakiam AS, Bergeron C, Lang AE Diffuse Lewy body disease presenting as multiple system atrophy. Can J Neurol Sci 1999, 26:127-131.
77. McKeith I, Burn D Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurologic Clinics: Dementia 2000, 865-883. WB Saunders, Philadelphia. S. DeKosky (Ed.).
78. Wenning GK, Seppi K, Jellinger K, et al. Survival of patients with dementia with Lewy bodies: a meta-analysis of 236 postmortem confirmed cases. Neurology 2000, 54(Suppl 3):391-392.
79. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002, 125:1070-1083.
80. Testa D, Monza D, Ferrarini M, et al. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 2001, 22:247-251.
81. Ben-Shlomo Y, Wenning GK, Tison F, et al. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997, 48:384-393.
82. Wenning GK, Ben Shlomo Y, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994, 117(Pt 4):835-845.
83. Abele M, Burk K, Schols L, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002, 125:961-968.
84. Gilman S, Little R, Johanns J, et al. Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000, 55:527-532.
85. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998, 13:16-19.
86. Boesch SM, Wenning GK, Ransmayr G, et al. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002, 72:300-303.
87. Wenning GK, Ben-Shlomo Y, Hughes A, et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000, 68:434-440.
88. Beck RO, Betts CD, Fowler CJ Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994, 151:1336-1341.
89. Braune S, Elam M, Baron R, et al. Assessment of blood pressure regulation. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 1999, 52:287-291.
90. Bannister R, Mathias C Investigation of autonomic disorders. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System 1999, 169-195. Oxford University Press, Oxford, UK. 4th ed. C. Mathias, R. Bannister (Eds.).
91. Braune S, Auer A, Schulte-Monting J, et al. Cardiovascular parameters: sensitivity to detect autonomic dysfunction and influence of age and sex in normal subjects. Clin Auton Res 1996, 6:3-15.
92. Braune S, Schulte-Monting J, Schwerbrock S, et al. Retest variation of cardiovascular parameters in autonomic testing. J Auton Nerv Syst 1996, 60:103-107.
93. Riley DE, Chelimsky TC Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. J Neurol Neurosurg Psychiatry 2003, 74:56-60.
94. Ziegler MG, Lake CR, Kopin IJ The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 1977, 296:293-297.
95. Polinsky RJ, Kopin IJ, Ebert MH, et al. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 1981, 31:1-7.
96. Goldstein DS, Polinsky RJ, Garty M, et al. Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 1989, 26:558-563.
97. Kaufmann H, Schatz IJ Pure autonomic failure. Primer on the Autonomic Nervous System 2004, 309-311. Elsevier, Amsterdam. D. Robertson (Ed.).
98. Baser SM, Brown RT, Curras MT, et al. Beta-receptor sensitivity in autonomic failure. Neurology 1991, 41:1107-1112.
99. Goldstein DS, Holmes C, Cannon RO, et al. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997, 336:696-702.
100. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999, 53:1020-1025.
101. Braune S The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001, 11:351-355.
102. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999, 67:189-194.
103. Takatsu H, Nagashima K, Murase M, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000, 284:44-45.
104. Taki J, Nakajima K, Hwang EH, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000, 27:566-573.
105. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1995, 53:230-234.
106. Yoshita M Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998, 155:60-67.
107. Goldstein DS, Holmes C, Li ST, et al. Cardiac sympathetic denervation in Parkinson's disease. Ann Intern Med 2000, 133:338-347.
108. 123I-metaiodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001, 70:781-783.
109. 123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001, 71:583-588.
110. 123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med 2003, 42:686-690.
111. Kirby R, Fowler C, Gosling J, et al. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986, 49:554-562.
112. Pramstaller PP, Wenning GK, Smith SJ, et al. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995, 58:618-621.
113. Palace J, Chandiramani VA, Fowler CJ Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997, 20:1396-1403.
114. Schwarz J, Kornhuber M, Bischoff C, et al. Electromyography of the external anal sphincter in patients with Parkinson's disease and multiple system atrophy: frequency of abnormal spontaneous activity and polyphasic motor unit potentials. Muscle Nerve 1997, 20:1167-1172.
115. Valldeoriola F, Valls-Sole J, Tolosa ES, et al. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 1995, 10:550-555.
116. Giladi N, Simon ES, Korczyn AD, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease. Muscle Nerve 2000, 23:731-734.
117. Colosimo C, Inghilleri M, Chaudhuri KR Parkinson's disease misdiagnosed as multiple system atrophy by sphincter electro-myography. J Neurol 2000, 247:559-561.
118. Vodusek DB Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord 2001, 16:600-607.
119. Polinsky RJ, Brown RT, Lee GK, et al. Beta-endorphin, ACTH, and catecholamine responses in chronic autonomic failure. Ann Neurol 1987, 21:573-577.
120. Kimber JR, Watson L, Mathias CJ Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997, 349:1877-1881.
121. Zoukos Y, Thomaides T, Pavitt DV, et al. Beta-adrenoceptor expression on circulating mononuclear cells of idiopathic Parkinson's disease and autonomic failure patients before and after reduction of central sympathetic outflow by clonidine. Neurology 1993, 43:1181-1187.
122. Clarke CE, Ray PS, Speller JM Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease. Lancet 1999, 353:1329-1330.
123. Tranchant C, Guiraud-Chaumeil C, Echaniz-Laguna A, et al. Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?. J Neurol 2000, 247:853-856.
124. Strijks E, van't Hof M, Sweep F, et al. Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with striatonigral degeneration. J Neurol 2002, 249:1206-1210.
125. Kimber J, Mathias CJ, Lees AJ, et al. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain 2000, 123(Pt 7):1422-1430.
126. Pellecchia MT, Salvatore E, Pivonello R, et al. Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. Neurol Sci 2001, 22:79-80.
127. Kimber J, Watson L, Mathias CJ Abnormal suppression of arginine-vasopressin by clonidine in multiple system atrophy. Clin Auton Res 1999, 9:271-274.
128. Kimber J, Watson L, Mathias CJ Neuroendocrine responses to levodopa in multiple system atrophy (MSA). Mov Disord 1999, 14:981-987.
129. Shannon J, Jordan J, Costa F, et al. The hypertension of autonomic failure and its treatment. Hypertension 1997, 30:1062-1067.
130. Shannon JR, Jordan J, Diedrich A, et al. Sympathetically mediated hypertension in autonomic failure. Circulation 2000, 101:2710-2715.
131. Wullner U, Klockgether T, Petersen D, et al. Magnetic resonance imaging in hereditary and idiopathic ataxia. Neurology 1993, 43:318-325.
132. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000, 54:697-702.
133. Drayer BP, Olanow W, Burger P, et al. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986, 159:493-498.
134. Pastakia B, Polinsky R, Di Chiro G, et al. Multiple system atrophy (Shy-Drager syndrome): MR imaging. Radiology 1986, 159:499-502.
135. O'Brien C, Sung JH, McGeachie RE, et al. Striatonigral degeneration: clinical, MRI, and pathologic correlation. Neurology 1990, 40:710-711.
136. Lang AE, Curran T, Provias J, et al. Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Can J Neurol Sci 1994, 21:311-318.
137. Schwarz J, Weis S, Kraft E, et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996, 60:98-101.
138. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998, 65:65-71.
139. Kraft E, Trenkwalder C, Auer DP T2 *-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology 2002, 59:1265-1267.
140. Konagaya M, Konagaya Y, Iida M Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 1994, 57:1528-1531.
141. Kraft E, Schwarz J, Trenkwalder C, et al. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy?. Arch Neurol 1999, 56:225-228.
142. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002, 58:575-580.
143. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003, 60:922-927.
144. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999, 45:65-74.
145. Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003, 18:1132-1138.
146. Barber R, Ballard C, McKeith IG, et al. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000, 54:1304-1309.
147. Barber R, Scheltens P, Gholkar A, et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999, 67:66-72.
148. Cousins DA, Burton EJ, Burn D, et al. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 2003, 61:1191-1195.
149. O'Brien JT, Paling S, Barber R, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001, 56:1386-1388.
150. Cordato NJ, Halliday GM, Harding AJ, et al. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 2000, 47:718-728.
151. Brenneis C, Wenning GK, Egger KE, et al. Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. Neuroreport 2004, 15:1711-1714.
152. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990, 28:547-555.
153. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990, 113(Pt 5):1539-1552.
154. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994, 57:278-284.
155. 11C-raclopride and positron emission tomography. Ann Neurol 1992, 31:184-192.
156. 11C]diprenorphine PET study. Brain 1995, 118(Pt 4):951-958.
157. De Volder AG, Francart J, Laterre C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989, 26:239-247.
158. Perani D, Bressi S, Testa D, et al. Clinical/metabolic correlations in multiple system atrophy: a fluorodeoxyglucose F 18 positron emission tomographic study. Arch Neurol 1995, 52:179-185.
159. 18F]fluorodeoxyglucose and PET. Mov Disord 1998, 13:268-274.
160. Ghaemi M, Hilker R, Rudolf J, et al. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002, 73:517-523.
161. Gilman S, Koeppe RA, Junck L, et al. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994, 36:166-175.
162. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000, 55:1575-1577.
163. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000, 162:247-256.
164. Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998, 51:125-130.
165. Brucke T, Djamshidian S, Bencsits G, et al. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000, 247(Suppl 4):IV/2-IV/7.
166. 2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002, 17:303-312.
167. 123I]Beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001, 16:1023-1032.
168. 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994, 57:1047-1056.
169. 123I-IBZM single photon emission computed tomography. Arch Neurol 1993, 50:513-516.
170. 2 receptor imaging and measurement with SPECT. Adv Neurol 1993, 60:494-500.
171. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992, 42:556-561.
172. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993, 43:S17-S20.
173. 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997, 24:320-325.
174. Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001, 56:643-649.
175. Ransmayr G, Seppi K, Donnemiller E, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med 2001, 28:1523-1528.
176. Walker Z, Costa DC, Ince P, et al. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet 1999, 354:646-647.
177. Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002, 73:134-140.
178. Heafield MT, Gammage MD, Nightingale S, et al. Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet 1996, 347:28-29.
179. Smit AA, Vermeulen M, Koelman JH, et al. Unusual recovery from acute panautonomic neuropathy after immunoglobulin therapy. Mayo Clin Proc 1997, 72:333-335.
180. Ramirez C, de Seze J, Stojkovic T, et al. Pure subacute pandysautonomia: an assessment of treatment with intravenous polyvalent immunoglobulins. Rev Neurol (Paris) 2004, 160:939-941.
181. Goetz CG, Tanner CM, Klawans HL The pharmacology of olivopontocerebellar atrophy. Adv Neurol 1984, 41:143-148.
182. Hughes AJ, Lees AJ, Stern GM Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990, 336:32-34.
183. Staal A, Meerwaldt JD, van Dongen KJ, et al. Non-familial degenerative disease and atrophy of brainstem and cerebellum: clinical and CT data in 47 patients. J Neurol Sci 1990, 95:259-269.
184. Hughes AJ, Colosimo C, Kleedorfer B, et al. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992, 55:1009-1013.
185. Parati EA, Fetoni V, Geminiani GC, et al. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol 1993, 16:139-144.
186. Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 1995, 59:144-151.
187. Gouider-Khouja N, Vidailhet M, Bonnet AM, et al. "Pure"
188. Fetoni V, Soliveri P, Monza D, et al. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999, 66:541-544.
189. Rossi P, Colosimo C, Moro E, et al. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000, 43:95-101.
190. Fearnley JM, Lees AJ Striatonigral degeneration: a clinico-pathological study. Brain 1990, 113(Pt 6):1823-1842.
191. Rajput AH, Rozdilsky B, Rajput A, et al. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990, 13:553-558.
192. Colosimo C, Albanese A, Hughes AJ, et al. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 1995, 52:294-298.
193. Wenning GK, Ben-Shlomo Y, Magalhaes M, et al. Clinico-pathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995, 58:160-166.
194. Quinn N Multiple system atrophy. Movement Disorders 3 1994, 262-281. Butterworth-Heinemann, London. C.D. Marsden, S. Fahn (Eds.).
195. Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002, 52:205-210.
196. Gnanalingham KK, Byrne EJ, Thornton A, et al. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997, 62:243-252.
197. Louis ED, Goldman JE, Powers JM, et al. Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord 1995, 10:188-194.
198. Louis ED, Klatka LA, Liu Y, et al. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997, 48:376-380.
199. Zesiewicz TA, Baker MJ, Dunne PB, et al. Diffuse Lewy body disease. Curr Treat Options Neurol 2001, 3:507-518.
200. Poewe W, Granata R, Geser F Pharmacologic treatment of Parkinson's disease. Movement Disorders: Neurological Principles and Practice 2004, 247-271. McGraw-Hill, New York. 2nd ed. R.L. Watts, W.C. Koller (Eds.).
201. Lees A The treatment of the motor disorder of multiple system atrophy. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System 1999, 357-363. Oxford University Press, Oxford, UK: Oxford. 4th ed. C. Mathias, R. Bannister (Eds.).
202. Wenning GK, Geser F, Poewe W Therapeutic strategies in multiple system atrophy (MSA). Mov Disord 2005, 20(Suppl 12):S67-S76.
203. Poewe W Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord 2005, 20(Suppl 12):S77-S82.
204. Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988, 38:951-956.
205. Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998, 51:120-124.
206. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997, 277:1046-1051.
207. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993, 95:38-48.
208. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003, 108:724-728.
209. Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001, 11:235-242.
210. Alam M, Smith G, Bleasdale-Barr K, et al. Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J Hypertens 1995, 13:1664-1669.
211. Raimbach SJ, Cortelli P, Kooner JS, et al. Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201-995) in chronic autonomic failure: haemodynamic and hormonal changes. Clin Sci (Lond) 1989, 77:623-628.
212. Mathias CJ, Fosbraey P, da Costa DF, et al. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986, 293:353-354.
213. Perera R, Isola L, Kaufmann H Erythropoietin improves orthostatic hypotension in primary autonomic failure. Neurology 1994, 44(Suppl):A363.
214. Biaggioni I, Robertson D, Krantz S, et al. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 1994, 121:181-186.
215. Hoeldtke RD, Streeten DH Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993, 329:611-615.
216. Perera R, Isola L, Kaufmann H Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995, 5:211-213.
217. Winkler AS, Marsden J, Parton M, et al. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord 2001, 16:233-239.
218. Vagaonescu TD, Saadia D, Tuhrim S, et al. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet 2000, 355:725-726.
219. Maclean A, Allen E Orthostatic hypotension and orthostatic tachycardia, treatment with the "head up" bed. JAMA 1940, 115:2162-2167.
220. Ten Harkel AD, Van Lieshout JJ, Wieling W Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992, 232:139-145.
221. Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol 2004, 3:93-103.
222. Jordan J, Shannon JR, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 1999, 10:35-42.
223. Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 2000, 79:191-195.
224. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998, 338:1397-1404.
225. Zesiewicz TA, Helal M, Hauser RA Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000, 15:305-308.
226. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001, 71:371-374.
227. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997, 336:1-7.
228. Eichhorn TE, Oertel WH Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001, 16:1176-1177.
229. Boeve BF, Silber MH, Ferman TJ Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003, 4:281-284.
230. Wild R, Pettit T, Burns A Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003, (3). CD003672.
231. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992, 305:673-678.
232. Ballard C, Grace J, McKeith I, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998, 351:1032-1033.
233. Sechi G, Agnetti V, Masuri R, et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:1043-1051.
234. McKeith IG, Ballard CG, Harrison RW Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995, 346:699.
235. Rich SS, Friedman JH, Ott BR Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995, 56:556-559.
236. Burke WJ, Pfeiffer RF, McComb RD Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998, 10:227-229.
237. Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999, 14:459-466.
238. Aarsland D, Ballard C, Larsen JP, et al. Marked neuroleptic sensitivity in dementia with Lewy bodies and Parkinson's disease. Nord J Psychiatry 2003, 57:94.
239. Iranzo A, Santamaria J, Tolosa E Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet 2000, 356:1329-1330.
240. Iranzo A, Santamaria J, Tolosa E, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004, 63:930-932.